局限性前列腺癌的综合分子分型揭示可预测非侵袭性疾病的肿瘤亚型
该研究对130例局限性前列腺癌术后标本进行多组学分子谱分析,基于DNA拷贝数、DNA甲基化和mRNA表达无监督分类,识别出三种分子亚型;其中一个亚型与无生化复发强相关,并在5个独立队列共746例样本中验证(P=3.41×10⁻⁸),提供36个转录组标志物,该亚型占所有局限性前列腺癌的22%。
要点
- 局限性前列腺癌存在三种分子亚型,其中一型与无生化复发强相关。
- 该非侵袭亚型在746例5队列中验证(P=3.41×10⁻⁸),占比约22%。
- 36个转录组标志物可稳健识别非侵袭亚型,优于常用预后分子签名。
核心结论
- 至少20%的局限性前列腺癌患者可基于分子亚型准确预测为非侵袭性疾病,应避免立即手术而选择主动监测。
研究设计与样本
- 对130例局限性前列腺癌根治术后标本进行多组学分子谱分析(DNA拷贝数、DNA甲基化、mRNA表达),采用无监督分类构建综合分型。
主要发现
- 描述三种前列腺癌分子亚型,具有特定分子特征和不同临床结局,其中一亚型与无生化复发强相关。
- 在5个独立队列共746例样本中验证该发现(P=3.41×10⁻⁸,N=746肿瘤样本)。
- 该分型方法优于最常用的预后分子签名,能准确识别非侵袭性疾病患者亚组。
- 提供36个转录组标志物可稳健识别该非侵袭亚型,其患病率估计占所有局限性前列腺癌的22%。
关键数值与推荐
- 基于DNA拷贝数、DNA甲基化和mRNA表达三个分子层面进行无监督分类。
- 非侵袭亚型在5个队列746例样本中验证P=3.41×10⁻⁸。
- 36个转录组标志物用于识别非侵袭亚型,患病率约22%。
临床怎么用
- 对局限性前列腺癌患者可考虑分子分型识别非侵袭亚型,避免立即根治性手术,转而纳入主动监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Management of localized prostate cancer (PCa) is a major clinical challenge since most of these cancers would not evolve but a majority of patients will still undergo a life-changing radical surgery. Molecular studies have shown that PCa can be classified according to their genomic alterations but none of the published PCa molecular classifications could identify a subtype corresponding to non-evolutive tumours. MATERIALS AND METHODS: Multi-omics molecular profiling was carried out on post-radical prostatectomy material from a cohort of 130 patients with localized PCa. We used unsupervised classification techniques to build a comprehensive classification of prostate tumours based on three molecular levels: DNA copy number, DNA methylation, and mRNA expression. Merged data from our cohort and The Cancer Genome Atlas cohort were used to characterize the resulting tumour subtypes. We measured subtype-associated risks of biochemical relapse using Cox regression models and survival data from five cohorts including the two aforementioned. RESULTS: We describe three PCa molecular subtypes associated with specific molecular characteristics and different clinical outcomes. Particularly, one subtype was strongly associated with the absence of biochemical recurrence. We validated this finding on 746 samples from 5 distinct cohorts (P = 3.41 × 10-8, N = 746 tumour samples), and showed that our subtyping approach outperformed the most popular prognostic molecular signatures to accurately identify a subset of patients with a non-evolutive disease. We provide a set of 36 transcriptomic biomarkers to robustly identify this subtype of non-evolutive cases whose prevalence was estimated to 22% of all localized PCa tumours. CONCLUSION: At least 20% of patients with localized PCa can be accurately predicted to have a non-evolutive disease on the basis of their molecular subtype. Those patients should not undergo immediate surgery and rather be placed under active surveillance.
引用
- Kamoun A, Cancel-Tassin G, Fromont G, et al. Comprehensive molecular classification of localized prostate adenocarcinoma reveals a tumour subtype predictive of non-aggressive disease. Ann Oncol. 2018. PMID: 29945238. doi:10.1093/annonc/mdy224
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。